African women are disproportionately affected by HIV infection and may experience non-AIDSrelated complications associated with inflammation. High-sensitivity C-reactive protein (hsCRP), D-dimer and transthyretin have been examined as inflammatory markers elsewhere, but it is unclear how they change over time in HIV-negative or HIV-positive African women with or without antiretroviral therapy (ART) initiation.
Introduction
Women are disproportionally affected by HIV infection, accounting for over half of HIV infections globally and 59% of HIV infections in eastern and southern Africa [1] . While the number of AIDS-related deaths in sub-Saharan Africa has fallen and the number of people accessing antiretroviral therapy (ART) has risen [1] , people living with HIV (PLWH) also face numerous non-AIDS-related comorbidities, including cardiovascular, liver and kidney diseases and some cancers [2] [3] [4] [5] [6] . Inflammation is one factor associated with this excess risk of non-AIDS-related events; inflammatory markers remain elevated above levels seen in people without HIV infection despite ART use and viral suppression [7] [8] [9] [10] . There are few longitudinal evaluations of these systemic inflammatory markers in HIV-infected women, despite known differences by gender in HIV natural history and immunity [11] [12] [13] [14] . As awareness increases of a double burden of HIV infection and chronic diseases, there is urgent need for research on these associations in African women [15] .
In PLWH, high-sensitivity C-reactive protein (hsCRP), D-dimer and transthyretin (prealbumin) have previously been examined as markers of inflammation. hsCRP is elevated in HIV-infected individuals compared with HIV-negative individuals, and independently predicts HIV-related mortality, HIV disease progression and risk for AIDS-and non-AIDS-related events [13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Higher D-dimer concentration in HIV infection has been associated with increased all-cause mortality and non-AIDS-related deaths [4, 9, [29] [30] [31] [32] [33] [34] , although results may be inconsistent in women [34] [35] [36] . Lower transthyretin concentration was associated with higher HIV-related mortality and a negative acute phase response [18, [37] [38] [39] . Longitudinal evaluation of these markers has not been well described in African women, and it is unclear how they change over time in HIV-negative women, or in PLWH with or without ART initiation. The results of previous studies are conflicting: hsCRP and Ddimer concentrations in PLWH have been observed to increase [4, 10, 19, [40] [41] [42] , remain unchanged [43] [44] [45] [46] [47] [48] [49] , or decrease [45, 46, [50] [51] [52] [53] after ART and/or over time. Few studies have examined longitudinal changes in transthyretin in HIV infection [39, 54] . Studies have mostly been limited to men, with short follow-up times, and to developed countries [40, 50, 55, 56] . The Rwanda Women's Interassociation Study and Assessment (RWISA) was an observational prospective cohort study of HIV-negative and HIV-positive women which collected historical, physical examination, laboratory and HIV treatment data every 6 months beginning in 2005. The study ended in December 2010. We examined levels of three markers of inflammation, hsCRP, D-dimer and transthyretin, at baseline and at follow-up of at least 2 years in 185 HIV-negative and 510 HIV-positive Rwandan women, all of whom were ART-na€ ıve at study entry. The goal of this study was to examine how these markers changed after ART initiation and over time in a population of Rwandan women including HIV-negative women, untreated HIV-positive women and HIV-positive women who were initially untreated but then initiated ART.
Methods

Parent study
Data were from the parent study Rwanda Women's Interassociation Study and Assessment (RWISA), a prospective observational cohort study that investigated the effectiveness and toxicity of ART in 710 antiretroviral-na€ ıve HIVinfected women using 226 uninfected women as controls. During the Rwandan genocide of 1994, an estimated 800 000 persons were murdered and 250 000 women were raped, with tens of thousands purposely infected with HIV [57] . HIV-infected and uninfected Rwandan women enrolled in RWISA between 16 May and 15 November 2005. The majority of HIV-infected and uninfected participants were recruited by Rwandan women's associations. These Rwandan associations mainly addressed psychosocial issues, including mental illness secondary to trauma during the 1994 genocide, economic self-reliance and HIV infection prevention or support. Some HIV-infected participants were also recruited from HIV clinics in Kigali prior to their initiation of ART. Study personnel used frequency matching during enrolment so that half of the HIV-infected and uninfected participants reported a history of experiencing genocidal rape. Eligible participants were ≥ 25 years old, able and willing to give informed consent and to be tested or retested for HIV infection, and able to return for bi-annual visits. Women were excluded if they had previously received any ART, with the allowable exception of prior single-dose nevirapine to prevent mother-to-child HIV transmission. Informed consent included a video describing and demonstrating the study, followed by a group question and answer period and then a private standard written informed consent process. RWISA was approved by the Rwanda National Ethics Committee and the Montefiore Medical Center Institutional Review Board (10-05-138E). The methods of RWISA have been previously described in detail [58] .
At study entry and at each subsequent visit, participants underwent a physical examination. Medical and social history was collected, including demographic characteristics, the exact date of ART initiation (verified by clinic data) and reported adherence to ART. Blood specimens were taken for determination of CD4 cell count, full blood count and other laboratory measures and serum was stored at À80°C. For this analysis, the baseline visit was defined as study entry for HIV-negative participants and HIV-infected ART-na€ ıve women not initiating ART during follow-up (ART noninitiators), and as the immediate pre-ART visit for women who initiated ART during follow-up (ART initiators).
Sample selection for this study
We included all women in the RWISA parent study with stored serum samples available at baseline (baseline visit) and at the latest follow-up visit which was greater than or equal to 2 years (follow-up visit). We considered ART use in two ways. Those ART-na€ ıve HIV-positive women who had indications for ART use (ART indicated), who were placed on ART after the baseline visit, and who were continued on ART at the followup visit were compared with HIV-negative women and HIV-positive women who were never placed on ART (ART was not indicated). We created a separate ART variable [antiretroviral (ARV) treatment] to capture the effect of initiating ARV treatment itself on each inflammatory marker. ART was initiated after the baseline visit, and inflammatory markers were again measured at least 2 years after initiation of ART, at the defined follow-up visit.
Additional exposure variables included associations that may have changed from the baseline visit to the follow-up visit. We included the effect of time between the baseline and follow-up visits, calculated as the difference in calendar dates in years between the baseline visit and the follow-up visit for each participant. For each model, we included the following follow-up time variables: follow-up time for HIV-negative women (set as 0 for HIV-positive women); follow-up time for untreated HIV-positive women (set as 0 for HIV-negative women and set to the time between baseline and ART initiation for HIV-positive women who initiated ART); and follow-up time for HIV-positive women on ART (set as 0 for HIV-negative women and 0 for untreated HIV-positive women).
The models also adjusted for the baseline visit date, the laboratory test date (the date on which samples were run), and participant age at the baseline visit. There was little smoking in this cohort reported at follow-up visit 2 (7%). Reported Depo-Provera (Depo) (Pfizer, New York, NY) hormone use was low at baseline (1%); however, there were a large number of missing measures. We examined variables both pre-and post-Depo use at baseline and follow-up; there were inconsistent patterns of association with the missing measures. Thus, smoking and Depo use were not included in our adjustment models.
Statistical analysis
hsCRP, D-dimer and transthyretin were examined for normality. D-dimer and hsCRP were left skewed and were thus log 10 transformed for linear regression and other comparative analyses. For D-dimer and hsCRP, results are presented on the log 10 scale.
We created three separate linear regression models, one for each of the inflammatory markers, with each model including covariates with associations at baseline, and covariates that changed from the baseline visit to the follow-up visit. Generalized estimating equation (GEE) models with independent correlation structure accounted for intra-person correlation of repeat measures. In our initial models, the variable 'ART indicated' did not remain independently statistically significant after adjustment for the HIV serostatus/CD4 quartile variable, and was thus dropped from the final model. The ARV treatment variable, however, remained independently significant in two of the models.
Results
We included all 695 nonpregnant women who had specimens available at the baseline visit and one follow-up visit at ≥ 2 years. The mean (AEstandard deviation) follow-up time was 2.89 (AE 0.67) years for HIV-negative women, 2.67 (AE 0.62) years for the ART noninitiators, and 2.37 years for HIV-positive ART initiators. Among the ART initiators, the mean time from baseline to ART initiation was 0.27 (AE 0.32) years with 2.10 (AE 0.90) years of follow-up on ART. Baseline and follow-up characteristics are shown in Table 1 . At baseline, HIV-negative women were older (mean 43.2 years) than both groups of HIV-positive women (mean 34.4 and 36.0 years for ART noninitiators and ART initiators, respectively; P ≤ 0.0001). Mean baseline body mass index (BMI) was similar among groups (P = 0.37). At follow-up, BMI had increased for all women (Table 1) . Among HIV-positive women at baseline (when all were ART-na€ ıve), the future ART noninitiators had higher CD4 counts than the ART initiators both at baseline (473 versus 211 cells/lL, respectively) and at follow-up (420 versus 371 cells/lL, respectively), indicating the more advanced immune suppression in the ART initiators. Mean hsCRP, D-dimer and transthyretin concentrations differed between HIV-negative women, HIV-positive ART noninitiators and HIV-positive ART initiators at baseline (P between groups: hsCRP, P < 0.0001; D-dimer, P = 0.003; transthyretin, P < 0.0001). Figure 1 (a-c) shows baseline and follow-up mean log hsCRP, log D-dimer and transthyretin values, with unadjusted P-value for the change. For hsCRP and D-dimer, log hsCRP and log D-dimer were used in the calculations, but the results have been exponentiated to the original scale for the figures. Mean hsCRP increased nonsignificantly from baseline to follow-up in the HIV-negative women (P = 0.40) and HIV-positive ART noninitiators (P = 0.36), and decreased nonsignificantly in the ART initiators (P = 0.20; Fig. 1a ). The mean D-dimer concentration decreased significantly in all groups from baseline to follow-up (HIV-negative women, P < 0.0001; HIV-positive ART noninitiators, P = 0.018; HIV-positive ART initiators, P < 0.0001; Fig. 1b) . The mean transthyretin concentration decreased significantly from baseline to follow-up in HIV-negative women (P = 0.0002) and HIVpositive ART noninitiators (P = 0.009), but increased significantly in ART initiators (P < 0.0001; Fig. 1c) . Table 2 shows the association of covariates with each of the markers of inflammation. Model results for D-dimer and hsCRP are shown on a log scale. Among HIV-infected women, for each quartile of CD4 increase (compared to HIV-negatives), mean log hsCRP concentration significantly decreased (0.47 mg/L for Q1, p < 0.0001; 0.32 mg/L for Q2, P < 0.0001; 0.27 mg/L for Q3 P < 0.0001; and 0.23 mg/L for Q4, P = 0.0004). The mean log D-dimer concentration also decreased per each quartile of CD4 count increased in HIV-positive (compared with HIV-negative) women, and this was significant for the first two quartiles (0.18 mg/L for Q1, P < 0.0001; 0.15 mg/L for Q2, P = 0.0001; 0.08 mg/L for Q3, P = 0.06; and 0.07 mg/L for Q4, P = 0.08). Among HIV-infected women, as the quartile of CD4 count increased, the mean difference in transthyretin concentration compared with HIV-negative women narrowed significantly (À6.17 mg/dL for Q1, P < 0.0001; À4.09 mg/dL for Q2, P < 0.00001; À2.58 mg/dL for Q3, P = 0.0001; and À2.55 mg/dL for Q4, P = 0.0001). In other words, women with more advanced HIV infection and lower CD4 counts (those in lower quartiles) had higher hsCRP, higher D-dimer and lower transthyretin concentrations.
A later baseline visit date was statistically associated with a lower expected mean log D-dimer concentration (À0.06 mg/L per one year later baseline visit date; P = 0.002) but not with differences in log hsCRP (+0.06 mg/dL per one year later baseline visit date; P = 0.15) or transthyretin (+0.13 mg/dL per one year later baseline visit date; P = 0.75). Age was not significantly associated with any of the markers. ARV treatment initiation after baseline was not independently associated with change in log hsCRP levels (0.08 mg/L; P = 0.36), but was independently associated with lower log D-dimer (À0.10 mg/L; P = 0.03) and higher transthyretin (2.77 mg/dL; P = 0.0008) concentrations at the follow-up visit.
Longer follow-up time among HIV-negative women was significantly associated with lower log D-dimer (À0.06 mg/L per year; P < 0.0001) and lower transthyretin (À0.28 mg/dL per year; P = 0.03) concentrations, but follow-up time was not significantly associated with log hsCRP (À0.01 mg/dL per year; P = 0.45). In untreated HIV-positive women, longer follow up time (without ART) was significantly associated with lower log D-dimer concentration (À0.06 mg/L per year; P = 0.0001) but not with change in log hsCRP (À0.009 mg/dL per year; P = 0.72) or transthyretin (À0.02 mg/dL per year; P = 0.91) level. Longer follow-up time among HIV-positive ART initiators was associated with lower log D-dimer concentration (À0.08 mg/L per year; P = 0.0001), but follow-up time was not associated with change in log hsCRP (À0.02 mg/dL per year; P = 0.55) or transthyretin (0.11 mg/dL per year; P = 0.77) concentration.
Discussion
In this cohort of 695 Rwandan women (HIV-negative women, HIV-positive, ART-na€ ıve women who did not initiate ART, and HIV-positive, ART-na€ ıve women who initiated ART after the baseline visit), we found that HIV infection with more advanced immune suppression was associated with higher inflammation, as measured by higher hsCRP and D-dimer concentrations and lower transthyretin concentration, compared with HIV-negative women. ARV treatment, which captures the cumulative effect of ART within the time frame from initiation of ART until ≥ 2 years of follow-up, was associated with decreased inflammation, indicated by lower D-dimer and higher transthyretin concentrations at follow-up, but was not associated with changes in hsCRP. Over ≥ 2 years of follow-up from baseline, we found no significant change in hsCRP from baseline to follow-up in any of the groups; D-dimer declined significantly in all groups; and transthyretin declined significantly in HIV-negative women and HIV-positive women not initiating ART, but increased in the HIV-positive women who initiated ART. Of the inflammatory markers we examined, hsCRP has been the most extensively examined in previous studies. We found that hsCRP was not associated with ART use, and over the ≥ 2 years of follow-up no group had a significant change in hsCRP. Our study is the first large study to investigate hsCRP in a population of African women. These findings are important because hsCRP is an acute-phase reactant which can fluctuate with infection, nutrition and inflammation [59] , and in this Rwandan population the levels might be elevated at baseline as a result of other non-HIV-related diseases or malnutrition. At baseline and at follow-up, however, the mean levels of hsCRP in HIV-negative women remained at average risk levels according to the Centers for Disease Control and Prevention and the American Heart Association [60] . Interestingly, women in a 2017 study of South Africans with a 22% prevalence of HIV infection had a high mean hsCRP concentration at baseline (3.3 mg/dL), which was also higher than the male mean baseline hsCRP concentration (3.1 mg/dL) [15] . HIV-positive women in our study had higher baseline values compared with HIV-negative women, consistent with other studies [21, 56, 61] .
Previous longitudinal studies of hsCRP, mostly in men, have shown varying results. Most recently, Funderberg et al. compared the effects of a tenofovir disoproxil fumarate regimen and a tenofovir alafenamide regimen on hsCRP levels in 194 participants (19% female). The mean hsCRP level at baseline was 1.6 mg/L and this did not change statistically in either arm after 48 weeks of treatment [45] . hsCRP decreased over 31 months in men in a small AIDS Clinical Trials Group (ACTG) study [53] , in HIV-infected patients on rosiglitazone in a small study [52] , and in about 30% of patients in each arm randomized to either abacavir/lamivudine or tenofovir/emtricitabine in the HEAT study [41] . However, later analysis of the HIV Study with Epizicom and Truvada (HEAT) study showed that, within the abacavir/lamivudine plus efavirenz arm, hsCRP actually increased up to 96 weeks after treatment initiation [62] . Multiple other studies have also observed increasing hsCRP over time with varying ART regimens [19, [63] [64] [65] or no change [46] [47] [48] [49] 66] . The longest of these studies found that hsCRP increased over 12 years, although this study was performed in 81 men only [19] . In the Strategies for Management of Anti-Retroviral Therapy Study (SMART), episodic use of ART guided by CD4 count (drug conservation arm) was compared with continuous ART; in both arms and in a group that had never taken ART or not taken ART in the past 6 months, hsCRP levels did not change significantly at 6 months [67] and they did not change significantly at 96 weeks in a similar study [48] .
Among women, results have also varied. Palella et al. [42] looked at hsCRP pre/post exposure to abacavir among 328 women in the Women's Interagency HIV Study and found that, after a mean of 4.2 years, hsCRP increased. Interestingly, a study by Shakuma et al. [68] found that, among HIV-positive individuals who were treated with an efavirenz-based ART regimen, hsCRP increased over 96 weeks in women but not in men. In a study in Thailand in which 62% of the participants were women, Calmy et al. [49] found no change in hsCRP at 12 weeks. There may be hormonal bases to these sex-specific differences in inflammatory markers, as other studies in non-HIV-infected people have found that associations of markers such as D-dimer and cardiovascular outcomes vary by sex, and oestrogen is known to be pro-thrombotic [69] [70] [71] . We found that ART use was associated with decline in D-dimer at follow-up, consistent with some other studies [4, 48, [72] [73] [74] . A recent study by Freiberg et al. following 249 active duty military personnel measured D-dimer and other inflammatory markers prior to HIV seroconversion, at least 6 months after seroconversion but before ART initiation, and 6 months after ART initiation. The D-dimer concentration increased significantly after seroconversion and decreased significantly after ART initiation, but remained significantly elevated above pre-conversion levels, despite viral suppression with ART [10] . Further, the D-dimer elevation was significantly associated with non-AIDS-related events at a median follow-up of 3.7 years [10] . In SMART, D-dimer levels rose at 4 weeks in the drug conservation arm (episodic use of ART) compared with those who were continuously suppressed with ART, and in this drug conservation arm, there was an increased risk of mortality [4] . One unexpected finding was that D-dimer decreased in all groups over time. In general, older age is a known risk factor for thrombosis [75] and we might expect a subtle rise, rather than a fall in D-dimer concentration among HIV-negative women. However, in our analysis age was not associated with any of the inflammatory markers. We also controlled for laboratory testing variability by randomizing the samples for testing and testing samples from the same participant in the same batch. This finding of decreased D-dimer concentration in all groups could also have been caused by an unmeasured effect of calendar time; however, we adjusted for this using the baseline visit date, laboratory test date and the follow-up times to account for the effects of normal ageing (HIV-negative follow-up time), the effects of HIV disease progression (HIV-positive follow-up time among those who did not start ART) and the effects of ART over time (HIV-positive follow-up time among those on ART). These findings need further investigation.
The longitudinal role of transthyretin has not been well investigated in the literature [76] . We found that, at baseline and follow-up, HIV infection in decreasing quartiles of CD4 count was progressively associated with lower transthyretin. At follow-up, all else being equal, ART use was associated with higher transthyretin concentration. These associations suggest that advanced HIV infection is inversely related to transthyretin concentration as an inflammatory marker and this association may be reversed by ART use. One small study in 92 HIV-positive and 52 HIV-negative breast-feeding mothers in South Africa also found lower transthyretin concentration in HIV-positive women (not on ART) compared with HIV-negative women at baseline [54] . These differences in transthyretin remained even after controlling for other acute-phase proteins (alpha-1 acid glycoprotein and hsCRP). Interestingly, transthyretin remained lower in HIV-positive compared with HIV-negative breast-feeding mothers after 6 months of follow-up, which could reflect ongoing inflammation. Again, in our population, even after adjusting for ART impact on change in CD4 level, those on ART experienced a significant increase in transthyretin, suggesting an additive improvement in inflammation.
The strengths of this study include a long follow-up time of at least 2 years, an all-female study population, treatment-na€ ıve status at baseline, and the comparison to a representative HIV-negative control group with similar potential exposures in this Rwandan population.
There are some limitations to our study. Although selfreported adherence to ART was high, we did not have viral load measurements, which could have aided in evaluation of the impact of ART. ARV treatment was also significantly associated with changes in transthyretin and Ddimer after ≥ 2 years. However, because the minimum time between the baseline and follow-up visits was 2 years, we could not assess the time course of post-ART initiation changes in the inflammatory markers during these first 2 years. For example, large changes could have occurred nearly immediately (i.e. within the first 30 days) after ART initiation followed by a plateau, or there could have been little change in inflammatory marker levels initially, with a large change occurring later. Finally, laboratory testing for these markers may vary depending on the assay, reagents and samples. We believe this was adequately controlled for as described above, but the possibility of other unmeasured confounders still exists. We did not have data on other potential confounders of systemic inflammation such as AIDS-defining illnesses or other common infections.
Conclusions
In summary, this is the first study to examine multiple markers of inflammation in an African population of HIV-negative and HIV-positive women. Taken together, the findings indicate that HIV infection and more advanced immune suppression were associated with inflammation, measured by higher hsCRP and D-dimer and lower transthyretin concentrations. After ≥ 2 years of ART use, independent of its effect on CD4 count, ARV treatment was significantly associated with a decrease in inflammation as measured by lower D-dimer levels and higher transthyretin levels. In contrast to the findings of some other studies, hsCRP did not change post-ART initiation, and we found no change in hsCRP over time in any of the groups.
